Equities research analysts predict that Voyager Therapeutics Inc (NASDAQ:VYGR) will post $3.00 million in sales for the current quarter, according to Zacks. Three analysts have made estimates for Voyager Therapeutics’ earnings, with estimates ranging from $2.00 million to $5.00 million. Voyager Therapeutics posted sales of $940,000.00 during the same quarter last year, which would indicate a positive year-over-year growth rate of 219.1%. The business is expected to issue its next earnings results on Thursday, May 9th.

According to Zacks, analysts expect that Voyager Therapeutics will report full-year sales of $29.40 million for the current financial year, with estimates ranging from $8.00 million to $81.57 million. For the next fiscal year, analysts expect that the business will post sales of $49.27 million, with estimates ranging from $8.00 million to $95.57 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that cover Voyager Therapeutics.

Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings data on Tuesday, February 26th. The company reported ($0.70) earnings per share for the quarter, missing the consensus estimate of ($0.66) by ($0.04). Voyager Therapeutics had a negative net margin of 1,158.79% and a negative return on equity of 120.82%. The firm had revenue of $2.01 million for the quarter, compared to the consensus estimate of $2.90 million.

VYGR has been the topic of several recent research reports. ValuEngine raised shares of Voyager Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Wednesday, April 3rd. Zacks Investment Research raised Voyager Therapeutics from a “hold” rating to a “buy” rating and set a $9.00 target price on the stock in a report on Wednesday, January 30th. BidaskClub upgraded Voyager Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, March 6th. Finally, Chardan Capital reiterated a “neutral” rating on shares of Voyager Therapeutics in a research report on Thursday, January 10th. Three research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $24.00.

NASDAQ VYGR traded up $0.10 during trading on Friday, hitting $20.81. The stock had a trading volume of 72,366 shares, compared to its average volume of 617,838. Voyager Therapeutics has a one year low of $7.76 and a one year high of $24.24. The company has a market cap of $679.41 million, a P/E ratio of -7.57 and a beta of 2.82.

In other news, major shareholder Neurocrine Biosciences Inc bought 4,179,728 shares of the stock in a transaction dated Tuesday, March 12th. The shares were acquired at an average price of $11.96 per share, with a total value of $49,989,546.88. Following the completion of the acquisition, the insider now directly owns 4,179,728 shares in the company, valued at $49,989,546.88. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. 33.60% of the stock is currently owned by company insiders.

Several institutional investors have recently bought and sold shares of the stock. Deutsche Bank AG lifted its holdings in Voyager Therapeutics by 96.3% in the fourth quarter. Deutsche Bank AG now owns 146,233 shares of the company’s stock valued at $1,374,000 after acquiring an additional 71,736 shares during the period. American Century Companies Inc. purchased a new position in shares of Voyager Therapeutics in the 4th quarter valued at about $235,000. Geode Capital Management LLC increased its holdings in shares of Voyager Therapeutics by 23.1% in the 4th quarter. Geode Capital Management LLC now owns 287,264 shares of the company’s stock valued at $2,700,000 after purchasing an additional 53,888 shares in the last quarter. Metropolitan Life Insurance Co. NY lifted its stake in shares of Voyager Therapeutics by 449.4% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 9,048 shares of the company’s stock valued at $85,000 after purchasing an additional 7,401 shares during the period. Finally, Paloma Partners Management Co purchased a new stake in Voyager Therapeutics during the fourth quarter worth about $155,000. Hedge funds and other institutional investors own 85.18% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trials for the treatment of advanced Parkinson's disease.

See Also: Market Capitalization

Get a free copy of the Zacks research report on Voyager Therapeutics (VYGR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.